| Literature DB >> 35954583 |
Yuki Sakamoto1, Mitsunobu Otsuru2, Takumi Hasegawa3, Masaya Akashi3, Shin-Ichi Yamada4, Hiroshi Kurita5, Masaya Okura6, Nobuhiro Yamakawa7, Tadaaki Kirita7, Souichi Yanamoto8, Masahiro Umeda2, Yuka Kojima9.
Abstract
The prognosis of oral cancer that has metastasized to the contralateral cervical lymph nodes is poor, although the appropriate treatment method has not been established because of its rarity. A multicenter retrospective study on the treatment and prognosis of pN2c oral cancer patients was conducted. We investigated the treatment and prognosis of 62 pN2c patients out of 388 pN+ patients with oral squamous cell carcinomas. Statistical analysis was performed on the various factors with overall survival (OS) and disease specific survival (DSS). In multivariate cox regression analysis, advanced T stage was significantly correlated with poor OS (p = 0.011) and DSS (p = 0.023) of patients with pN2c neck. In pN2c patients, OS, DSS, and neck control was not different between those undergoing ipsilateral neck dissection initially and those undergoing bilateral neck dissection. Thus, contralateral elective neck dissection is not recommended. The most important risk factor for prognosis in pN2c oral cancer patients is advanced T stage. No evidence was found to recommend contralateral elective neck dissection in clinically N1/2b patients. Therefore, the indication for contralateral elective neck dissection in N1/2b patients should be carefully determined in consideration of individual conditions.Entities:
Keywords: lymphatic metastasis; mouth neoplasms; neck dissection; prognosis; risk factor
Mesh:
Year: 2022 PMID: 35954583 PMCID: PMC9368347 DOI: 10.3390/ijerph19159229
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Patient characteristics.
| Variable | Number of Patients/Mean ± SD | ||||
|---|---|---|---|---|---|
| pN1 | pN2b | pN2c | Total | ||
| Age | years | 64.0 ± 13.7 | 65.9 ± 12.0 | 65.8 ± 10.4 | 65.4 ± 12.2 |
| Sex | male | 75 (68.8%) | 133 (61.3%) | 48 (77.4%) | 256 (66.0%) |
| female | 34 (31.2%) | 84 (38.7%) | 14 (22.6%) | 132 (34.0%) | |
| Primary site | tongue | 51 (46.8%) | 87 (40.1%) | 25 (40.3%) | 163 (42.0%) |
| lower gingiva | 24 (22.0%) | 59 (27.2%) | 8 (12.9%) | 91 (23.5%) | |
| upper gingiva/hard palate | 12 (11.0%) | 32 (14.7%) | 12 (19.4%) | 56 (14.4%) | |
| floor of the mouth | 12 (11.0%) | 17 (7.8%) | 15 (24.2%) | 44 (11.3%) | |
| buccal mucosa | 8 (7.3%) | 18 (8.3%) | 0 (0%) | 26 (6.7%) | |
| others | 2 (1.8%) | 4 (1.8%) | 2 (3.2%) | 8 (2.1%) | |
| Histological grade | well/moderately differentiated | 96 (88.1%) | 177 (81.6%) | 56 (90.3%) | 329 (84.8%) |
| poorly differentiated | 8 (7.3%) | 31 (14.3%) | 6 (9.7%) | 45 (11.6%) | |
| unknown | 5 (4.6%) | 9 (4.1%) | 0 (0%) | 14 (3.6%) | |
| Clinical T stage | T1 | 7 (6.4%) | 4 (1.8%) | 4 (6.5%) | 15 (3.9%) |
| T2 | 47 (43.1%) | 84 (38.7%) | 18 (29.0%) | 149 (38.4%) | |
| T3 | 20 (18.3%) | 37 (17.1%) | 15 (24.2%) | 72 (18.6%) | |
| T4a | 24 (22.0%) | 72 (33.2%) | 24 (38.7%) | 120 (30.9%) | |
| T4b | 10 9.2%) | 17 (7.8%) | 1 (1.6%) | 28 (7.2%) | |
| unknown | 1 (0.9%) | 3 (1.4%) | 0 (0%) | 4 (1.0%) | |
| Clinical N stage | cN0 | 27 (24.8%) | 30 (13.8%) | 11 (17.7%) | 68 (17.5%) |
| cN1 | 55 (50.5%) | 51 (23.5%) | 6 (9.7%) | 112 (28.9%) | |
| cN2a | 0 (0%) | 1 (0.5%) | 1 (1.6%) | 2 (0.5%) | |
| cN2b | 20 (18.3%) | 107 (49.3%) | 17 (27.4%) | 145 (37.4%) | |
| cN2c | 6 (5.5%) | 21 (9.7%) | 26 (41.9%) | 52 (13.4%) | |
| cN3 | 1 (0.9%) | 7 (3.2%) | 1 (1.6%) | 9 (2.3%) | |
| Total | 109 | 217 | 62 | 388 | |
Figure 1OS, DSS, and final status of patients with pN1, pN2b and pN2c neck.
Factors related to the prognosis of patients with pN2c necks (univariate analysis).
| Variable | OS | DSS | |
|---|---|---|---|
| Age | 65 or more/64 or less | 0.127 | 0.111 |
| Sex | male/female | 0.383 | 0.878 |
| Primary site | others/tongue or floor of the mouth | 0.922 | 0.912 |
| Tumor location | including midline/one side only | 0.763 | 0.980 |
| Deep invasion | invading to the midline/one side only | 0.322 | 0.431 |
| T stage | T3–4/T1–2 | * 0.031 | * 0.007 |
| cN stage | N2–3/N0–1 | 0.154 | 0.246 |
| Differentiation | poorly differentiated/well or moderately | 0.121 | 0.195 |
| Initial neck dissection | bilateral/ipsilateral | 0.500 | 0.406 |
| Neoadjuvant chemo-/radiotherapy | (+)/(−) | 0.673 | 0.515 |
| Postoperative chemo-/radiotherapy | (+)/(−) | 0.968 | 0.787 |
| Number of positive nodes in the ipsilateral neck | 4 or more/3 or less | 0.654 | 0.755 |
| Extranodal spread in the ipsilateral neck | (+)/(−) | * 0.002 | * 0.006 |
| Level of metastasis in the ipsilateral neck | level 4–5/level 1–3 | * 0.032 | * 0.004 |
| Number of positive nodes in the contralateral neck | 4 or more/3 or less | 0.768 | 0.281 |
| Extranodal spread in the contralateral neck | (+)/(−) | 0.053 | 0.429 |
| Level of metastasis in the contralateral neck | level 4–5/level 1–3 | 0.974 | 0.579 |
Log rank test, * p < 0.05, Abbreviation: OS: overall survival; DSS: disease specific survival.
Factors related to the prognosis of patients with pN2c necks (multivariate analysis).
| Variable | Hazard Ratio | 95% Confidence Interval | ||
|---|---|---|---|---|
| (i) OS | ||||
| T stage | T3–4/T1–2 | * 0.006 | 2.753 | 1.344–5.637 |
| Extranodal spread in the ipsilateral neck | (+)/(−) | 0.117 | 1.756 | 0.869–3.548 |
| Level of metastasis in the ipsilateral neck | level 4–5/level 1–3 | * 0.048 | 2.205 | 1.008–4.821 |
| Extranodal spread in the contralateral neck | (+)/(−) | 0.160 | 0.619 | 0.317–1.208 |
| (ii) DSS | ||||
| T stage | T3–4/T1–2 | * 0.003 | 3.883 | 1.569–9.609 |
| Extranodal spread in the ipsilateral neck | (+)/(−) | 0.118 | 1.847 | 0.855–3.988 |
| Level of metastasis in the ipsilateral neck | level 4–5/level 1–3 | * 0.020 | 2.623 | 1.162–3.988 |
Cox regression analysis, * p < 0.05, Abbreviation: OS: overall survival; DSS: disease specific survival.
Figure 2OS, DSS, and the final status of patients with pN2c necks who underwent ipsilateral neck dissection initially and bilateral neck dissection initially.
Figure 3OS, DSS, and the final status of patients with pN2c necks excluding clinical N2c necks, who underwent ipsilateral neck dissection initially and bilateral neck dissection initially.
Factors related to the prognosis of patients with pN2c necks (cancer of the tongue or the floor of the mouth, univariate analysis).
| Variable | OS | DSS | |
|---|---|---|---|
| Age | 65 or more/64 or less | 0.552 | 0.378 |
| Sex | male/female | 0.453 | 0.214 |
| Tumor location | including midline/one side only | 0.626 | 0.954 |
| Deep invasion | invading to the midline/one side only | 0.264 | 0.247 |
| T stage | T3–4/T1–2 | 0.086 | * 0.034 |
| cN stage | N2–3/N0–1 | 0.234 | 0.185 |
| Differentiation | poorly differentiated/well or moderately | 0.734 | 0.956 |
| Initial neck dissection | bilateral/ipsilateral | 0.547 | 0.298 |
| Neoadjuvant chemo-/radiotherapy | (+)/(−) | 0.599 | 0.722 |
| Postoperative chemo-/radiotherapy | (+)/(−) | 0.760 | 0.674 |
| Number of positive nodes in the ipsilateral neck | 4 or more/3 or less | 0.193 | 0.217 |
| Extranodal spread in the ipsilateral neck | (+)/(−) | * 0.016 | 0.080 |
| Level of metastasis in the ipsilateral neck | level 4–5/level 1–3 | * 0.001 | * <0.001 |
| Number of positive nodes in the contralateral neck | 4 or more/3 or less | 0.764 | 0.355 |
| Extranodal spread in the contralateral neck | (+)/(−) | 0.373 | 0.863 |
| Level of metastasis in the contralateral neck | level 4–5/level 1–3 | 0.850 | 0.712 |
Log rank test, * p < 0.05, Abbreviation: OS: overall survival; DSS: disease specific survival.
Factors related to the prognosis of patients with pN2c necks (cancer of the tongue or the floor of the mouth, multivariate analysis).
| Variable | Hazard Ratio | 95% Confidence Interval | ||
|---|---|---|---|---|
| (i) OS | ||||
| T stage | T3–4/T1–2 | 0.244 | 1.597 | 0.727–3.508 |
| Extranodal spread in the ipsilateral neck | (+)/(−) | 0.094 | 2.020 | 0.887–4.598 |
| Level of metastasis in the ipsilateral neck | level 4–5/level 1–3 | * 0.019 | 3.057 | 1.198–7.797 |
| (ii) DSS | ||||
| T stage | T3–4/T1–2 | 0.151 | 2.063 | 0.787–5.408 |
| Extranodal spread in the ipsilateral neck | (+)/(−) | 0.437 | 1.463 | 0.561–3.817 |
| Level of metastasis in the ipsilateral neck | level 4–5/level 1–3 | * 0.006 | 4.123 | 1.498–11.348 |
Cox regression analysis, * p < 0.05, Abbreviation: OS: overall survival; DSS: disease specific survival.
Figure 4OS, DSS, and final status of the tongue or the floor of the mouth cancer patients with pN2c necks who underwent ipsilateral neck dissection initially and bilateral neck dissection initially.